Curasight strengthens its strategic position with the acquisition of TRT Innovations ApS
Copenhagen, Denmark, 10 February 2022 - Curasight A/S (“Curasight” or the “Company”) has today signed and completed an agreement to acquire the early-stage R&D company TRT Innovations ApS. Curasight intends to expand and accelerate its clinical programs and is strengthening the therapeutic platform.Curasight has signed and completed an agreement to acquire all outstanding shares in TRT Innovations, which is a Danish early-stage R&D company focusing on research activities related to cancer therapy. Besides its R&D activities, TRT Innovations reached a net loss of DKK 113,000 for the